Clinical Scorecard: Hypertension: Biomarkers Clarify Heart Failure Risk

At a Glance

Key Highlights

• Prediabetes with myocardial injury increases heart failure risk by over 10 times.
• High-sensitivity cardiac troponin I and NT-proBNP are critical biomarkers.
• Incidence rate of heart failure events was 4.6 per 1,000 person-years.
• A 25% increase in biomarkers correlates with higher heart failure risk.
• Observational study design limits causal inference.

Guideline-Based Recommendations

Diagnosis

• Use fasting plasma glucose to classify prediabetes (100-125 mg/dL).
• Measure hs-cTnI and NT-proBNP for myocardial injury and stress.

Management

• Monitor patients with hypertension for biomarker elevation.
• Consider prediabetes as a risk modifier for heart failure.

Monitoring & Follow-up

• Regularly assess hs-cTnI and NT-proBNP levels in at-risk populations.
• Track changes in biomarker levels over time.

Risks

• Prediabetes without biomarker elevation does not significantly increase heart failure risk.
• Misclassification of prediabetes may occur with single glucose measurements.

Patient & Prescribing Data

Hypertensive adults with prediabetes and no history of heart failure.

Focus on managing blood pressure and monitoring biomarkers to mitigate heart failure risk.

Clinical Best Practices

• Integrate biomarker assessment into routine care for hypertensive patients.
• Educate patients on the implications of prediabetes and myocardial injury.

References

• JAMA Cardiology